Nicola Valeri

List of Publications by Year
in descending order

87 papers	6,565 citations	109137 35 h-index	66788 78 g-index
90 all docs	90 docs citations	90 times ranked	11523 citing authors

#	Article	IF	Citations
1	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. Frontiers in Endocrinology, 2022, 13, 834075.	1.5	5
2	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut, 2021, 70, 1632-1641.	6.1	24
3	MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discovery, 2021, 11, 1228-1247.	7.7	45
4	Vault RNAs: hidden gems in RNA and protein regulation. Cellular and Molecular Life Sciences, 2021, 78, 1487-1499.	2.4	26
5	Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer. Clinical Cancer Research, 2021, 27, 2964-2966.	3.2	0
6	Challenges and perspectives for immunotherapy inÂoesophageal cancer: A look to the future (Review). International Journal of Molecular Medicine, 2021, 47, .	1.8	3
7	Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2021, 6, 515-516.	3.7	1
8	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 2021, 28, 2970-2982.	5.0	13
9	A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer. Cellular Oncology (Dordrecht), 2021, 44, 1197-1206.	2.1	2
10	Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nature Communications, 2021, 12, 366.	5.8	138
11	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes, 2021, 12, 33.	1.0	23
12	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	5.8	10
13	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. Cancer Imaging, 2021, 21, 67.	1.2	4
14	Modulation of Biliary Cancer Chemoâ€Resistance Through MicroRNAâ€Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, 2020, 72, 982-996.	3.6	30
15	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. Annals of Hematology, 2020, 99, 105-112.	0.8	6
16	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. Frontiers in Oncology, 2020, 10, 1634.	1.3	2
17	MicroRNAs as mediators of drug resistance mechanisms. Current Opinion in Pharmacology, 2020, 54, 44-50.	1.7	19
18	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. Cancers, 2020, 12, 2452.	1.7	20

#	Article	IF	Citations
19	Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients. Gastrointestinal Disorders, 2020, 2, 212-235.	0.4	7
20	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrettâ€™s carcinogenesis. Pathology Research and Practice, 2020, 216, 152907.	1.0	17
21	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist, 2020, 25, 481-487.	1.9	77
22	Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nature Communications, 2020, 11, 1923.	5.8	79
23	MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Targeted Oncology, 2020, 15, 261-278.	1.7	183
24	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patientsâ€™ Prognosis. International Journal of Surgical Pathology, 2019, 27, 816-835.	0.4	8
25	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology, 2019, 143, 153-163.	2.0	49
26	A MYCâ€“GCN2â€“eIF2Î± negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nature Cell Biology, 2019, 21, 1413-1424.	4.6	65
27	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 2019, 37, 3392-3400.	0.8	293
28	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. British Journal of Cancer, 2019, 121, 257-263.	2.9	53
29	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. Epigenomics, 2019, 11, 587-604.	1.0	29
30	Streamlining Detection of Fusion Genes in Colorectal Cancer: Having â€œFaithâ€•in Precision Oncology in the (Tissue) â€œAgnosticâ€•Era. Cancer Research, 2019, 79, 1041-1043.	0.4	15
31	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. Clinical Cancer Research, 2019, 25, 3830-3838.	3.2	42
32	Class(y) Dissection of BRAF Heterogeneity: Beyond Non-V600. Clinical Cancer Research, 2019, 25, 6896-6898.	3.2	7
33	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. European Journal of Surgical Oncology, 2019, 45, 1479-1482.	0.5	10
34	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	1.7	14
35	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene, 2019, 38, 1717-1733.	2.6	29
36	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer, 2019, 18, 64-71.e1.	1.0	10

#	Article	IF	Citations
37	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	6.0	1,199
38	Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy â€“ results from the <scp>MRC OE</scp>02 oesophageal cancer trial. Histopathology, 2018, 72, 1180-1188.	1.6	31
39	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 2018, 8, 1445.	1.6	55
40	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5.	0.6	94
41	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	6.1	59
42	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 159-171.	0.8	10
43	LONG-NONCODING RNAs in gastroesophageal cancers. Non-coding RNA Research, 2018, 3, 195-212.	2.4	39
44	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer Cell International, 2018, 18, 131.	1.8	7
45	Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cellular and Molecular Life Sciences, 2018, 75, 4151-4162.	2.4	150
46	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discovery, 2018, 8, 1270-1285.	7.7	187
47	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 280-284.	1.0	33
48	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica, 2018, 103, 2049-2058.	1.7	13
49	Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. Frontiers in Oncology, 2018, 8, 226.	1.3	56
50	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. Targeted Oncology, 2018, 13, 423-436.	1.7	5
51	Translational research and application of basic biology to clinical trial development in GI cancers. Annals of Translational Medicine, 2018, 6, 164-164.	0.7	6
52	The molecular landscape of colitis-associated carcinogenesis. Digestive and Liver Disease, 2017, 49, 326-330.	0.4	34
53	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 2017, 66, 1268-1277.	6.1	75
54	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. JAMA Oncology, 2017, 3, 1197.	3.4	398

#	Article	IF	Citations
55	Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. American Journal of Clinical Pathology, 2017, 147, 301-308.	0.4	23
56	Characterisation of the immune-related transcriptome in resected biliary tract cancers. European Journal of Cancer, 2017, 86, 158-165.	1.3	47
57	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clinical Cancer Research, 2017, 23, 7543-7549.	3.2	12
58	Combining Molecularly Targeted Agents: Is More Always Better?. Clinical Cancer Research, 2017, 23, 1123-1125.	3.2	6
59	A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials, 2017, 18, 394.	0.7	72
60	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget, 2017, 8, 111795-111806.	0.8	6
61	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 2016, 37, 852-857.	1.3	15
62	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. British Journal of Cancer, 2016, 115, 1343-1350.	2.9	27
63	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Journal of Clinical Oncology, 2016, 34, 2721-2727.	0.8	214
64	Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis. Oncotarget, 2016, 7, 4915-4924.	0.8	26
65	From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. Histology and Histopathology, 2016, 31, 25-32.	0.5	13
66	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of Oncology, 2015, 26, 1936-1941.	0.6	24
67	An evaluation and replication of mi<scp>RNA</scp>s with disease stage and colorectal cancerâ€specific mortality. International Journal of Cancer, 2015, 137, 428-438.	2.3	119
68	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget, 2014, 5, 7162-7171.	0.8	35
69	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. Cancer Cell, 2014, 25, 469-483.	7.7	267
70	c-Src drives intestinal regeneration and transformation. EMBO Journal, 2014, 33, 1474-91.	3.5	56
71	An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer Epidemiology, 2014, 38, 583-590.	0.8	26
72	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology, 2012, 25, 1333-1344.	2.9	48

#	Article	IF	Citations
73	rs4919510 in hsa-mir-608 Is Associated with Outcome but Not Risk of Colorectal Cancer. PLoS ONE, 2012, 7, e36306.	1.1	85
74	Anti-miR-135b in colon cancer treatment: Results from a preclinical study.. Journal of Clinical Oncology, 2012, 30, 457-457.	0.8	2
75	MicroRNAs in the Pathogenesis of Cancer. Seminars in Oncology, 2011, 38, 724-733.	0.8	181
76	Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 786-791.	3.3	207
77	Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2011, 17, 5649-5655.	3.2	17
78	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	3.8	256
79	Abstract 1178: Involvement of MEG3, a long non-coding RNA, in hepatocellular cancer (HCC). , 2011, , .		0
80	Comprehensive miRNA profiling of surgically staged endometrial cancer. American Journal of Obstetrics and Gynecology, 2010, 202, 656.e1-656.e8.	0.7	77
81	MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21098-21103.	3.3	333
82	Hepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant Hepatocytes. Clinical Cancer Research, 2010, 16, 957-966.	3.2	108
83	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	3.3	306
84	Abstract 4086: Ultraconserved non-coding RNAs are involved in human hepatocellular cancer growth. , 2010, , .		0
85	MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. Carcinogenesis, 2009, 30, 912-917.	1.3	31
86	Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mammalian Genome, 2009, 20, 573-80.	1.0	91
87	Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics and Proteomics, 2009, 6, 195-204.	1.0	22